Summit Creek Advisors LLC Purchases New Position in Veracyte, Inc. $VCYT

Posted by Francis Steltz on Aug 19th, 2026

Summit Creek Advisors LLC acquired a new position in Veracyte, Inc. (NASDAQ:VCYT – Free Report) during the second quarter, Holdings Channel reports. The institutional investor acquired 118,956 shares of the biotechnology company’s stock, valued at approximately $6,986,000. Veracyte makes up about 2.4% of Summit Creek Advisors LLC’s portfolio, making the stock its 13th largest holding.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in VCYT. GAMMA Investing LLC lifted its stake in Veracyte by 21.2% in the second quarter. GAMMA Investing LLC now owns 1,121 shares of the biotechnology company’s stock valued at $66,000 after acquiring an additional 196 shares during the last quarter. Oregon Public Employees Retirement Fund increased its stake in shares of Veracyte by 2.3% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 18,100 shares of the biotechnology company’s stock worth $762,000 after purchasing an additional 400 shares during the last quarter. California State Teachers Retirement System increased its stake in shares of Veracyte by 0.8% during the 2nd quarter. California State Teachers Retirement System now owns 71,095 shares of the biotechnology company’s stock worth $1,922,000 after purchasing an additional 566 shares during the last quarter. O Shaughnessy Asset Management LLC raised its holdings in shares of Veracyte by 7.9% during the 4th quarter. O Shaughnessy Asset Management LLC now owns 7,894 shares of the biotechnology company’s stock valued at $332,000 after purchasing an additional 576 shares in the last quarter. Finally, Smartleaf Asset Management LLC raised its holdings in shares of Veracyte by 159.8% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,104 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 679 shares in the last quarter.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on VCYT shares. Zacks Research upgraded shares of Veracyte from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 11th. Morgan Stanley reduced their price target on Veracyte from $47.00 to $44.00 and set an “underweight” rating for the company in a research report on Tuesday, August 4th. Needham & Company LLC upped their price target on Veracyte from $57.00 to $69.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. UBS Group increased their price objective on Veracyte from $48.00 to $52.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Finally, Canaccord Genuity Group cut their price objective on Veracyte from $60.00 to $50.00 and set a “hold” rating on the stock in a research note on Monday, August 3rd. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Veracyte presently has an average rating of “Moderate Buy” and a consensus price target of $54.33.

Get Our Latest Research Report on Veracyte

Insiders Place Their Bets

In related news, CAO Jonathan Wygant sold 24,000 shares of the business’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $45.40, for a total transaction of $1,089,600.00. Following the completion of the transaction, the chief accounting officer owned 45,434 shares of the company’s stock, valued at approximately $2,062,703.60. The trade was a 34.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider John Leite sold 13,975 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $50.07, for a total value of $699,728.25. Following the sale, the insider owned 132,305 shares of the company’s stock, valued at approximately $6,624,511.35. The trade was a 9.55% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 186,492 shares of company stock valued at $9,240,797 in the last ninety days. Company insiders own 1.60% of the company’s stock.

Veracyte Trading Down 3.3%

NASDAQ:VCYT opened at $40.68 on Wednesday. The firm has a market capitalization of $3.27 billion, a PE ratio of 28.85 and a beta of 1.95. Veracyte, Inc. has a 1 year low of $28.25 and a 1 year high of $60.91. The firm’s fifty day simple moving average is $53.06 and its 200 day simple moving average is $42.56.

Veracyte (NASDAQ:VCYT – Get Free Report) last released its earnings results on Thursday, July 30th. The biotechnology company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.13. Veracyte had a net margin of 20.37% and a return on equity of 9.26%. The firm had revenue of $150.32 million during the quarter, compared to analyst estimates of $144.59 million. During the same quarter in the previous year, the business earned $0.44 EPS. The business’s revenue was up 15.5% on a year-over-year basis. As a group, analysts anticipate that Veracyte, Inc. will post 1.32 EPS for the current fiscal year.

Veracyte Profile

(Free Report)

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.